ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
19 announcements
Godavari Drugs Ltd reported revenue from operations of ₹28.2 Cr (+6.0% YoY) and net profit of ₹1 Cr (+0.0% YoY) for Q2 FY27.
Godavari Drugs will hold a board meeting on 11 November 2026 to consider unaudited results for the quarter and half year ended 30 September 2026. The trading window stays closed until 48 hours after the results are declared.
Godavari Drugs allotted 7,86,690 equity shares to promoter-category allottees on conversion of warrants. The balance consideration of Rs 5.25 Crore was received at an issue price of Rs 89.
Godavari Drugs filed its quarterly shareholding pattern for the period ended 30 September 2026. The filing is a routine Regulation 31 disclosure with no transaction.
Godavari Drugs Limited changed its Corporate Identification Number (CIN) following an alteration to its Memorandum of Association's Object Clause. The Ministry of Corporate Affairs registered the change on October 16, 2026.
Godavari Drugs Limited's board approved availing working capital limits of Rs. 34 Crore from ICICI Bank. The facility is within existing shareholder-approved borrowing limits.
Godavari Drugs held its 38th Annual General Meeting on September 25, 2026, via video conferencing. Shareholders approved financial statements, director re-appointment, and object clause alteration.
Godavari Drugs Limited will close its register of members and share transfer books from September 19 to September 25, 2026, for its 38th Annual General Meeting.
Godavari Drugs approved altering its Memorandum of Association to add a nutraceuticals business object. A revised notice for the 38th AGM was also approved.
Godavari Drugs Limited allotted 7,86,690 equity shares to the promoter category following warrant conversion. The company received Rs. 5.25 Crore, representing the final 75% payment.
Godavari Drugs Ltd reported revenue from operations of ₹28 Cr (+17.6% YoY) and net profit of ₹1.1 Cr (+10.0% YoY) for Q1 FY27.
Godavari Drugs Limited has scheduled a board meeting for August 24, 2026, to consider and approve the un-audited financial results for the quarter ended June 30, 2026.
Godavari Drugs Ltd filed its quarterly shareholding pattern as of June 30, 2026. The document provides a detailed breakdown of promoter and public holdings.
Godavari Drugs Limited reported zero deviation in the utilization of ₹44.12 Crore raised through a preferential allotment. The funds are being deployed for capital expenditure.
Godavari Drugs Ltd reported revenue from operations of ₹33.2 Cr (+30.2% YoY) and net profit of ₹1.3 Cr (+44.4% YoY) for Q4 FY26.
Godavari Drugs Ltd reported annual revenue of ₹105.81 Crore for FY2026. The Board approved the audited results and appointed new internal and cost auditors.
Godavari Drugs scheduled a board meeting for May 27, 2026, to approve annual audited financial results. The trading window remains closed until May 29, 2026.
Godavari Drugs Limited filed its Annual Secretarial Compliance Report for the financial year 2025-26. The report confirms overall regulatory adherence with minor observations on historical filing delays.
Godavari Drugs Limited clarified to BSE that recent share price movements are entirely market-driven. The company confirmed it has no undisclosed price-sensitive information and remains compliant with SEBI listing regulations regarding timely disclosures.